{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T16:12:47Z","timestamp":1793895167628,"version":"4.8.0"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T00:00:00Z","timestamp":1767312000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The optimal combination therapy for heart failure with reduced ejection fraction (HFrEF) involving sodium-glucose transporter 2 inhibitors (SGLT2i), angiotensin receptor\u2013neprilysin inhibitors (ARNI), and conventional triple therapy remains uncertain due to the lack of direct comparative evidence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a Bayesian network meta-analysis of randomized controlled trials (RCTs) comparing six treatment regimens. Primary outcome was the composite of cardiovascular death and hospitalization. Secondary outcomes included all-cause mortality, Kansas City Cardiomyopathy Questionnaire (KCCQ) scores, 6-minute walk distance (6MWD), N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels, and adverse events (hypotension, hyperkalemia, renal events). All analyses were performed under a Bayesian statistical framework, and the relative efficacy and safety of the six regimens were ranked using surface under the cumulative ranking curve (SUCRA) probabilities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 22 studies (21 RCTs) involving 24,499 patients were included. For the primary composite outcome, Sotagliflozin-based quadruple therapy ranked first (SUCRA: 90.8%; OR: 0.49, 95%CI: 0.16 to 1.47). Dapagliflozin+triple therapy (SUCRA: 76.8%; OR: 0.83, 95%CI: 0.69 to 0.98) and ARNI+BB+MRA (SUCRA: 76.6%; OR: 0.83, 95%CI: 0.75 to 0.92) demonstrated significant reductions in all-cause mortality. ARNI-based triple therapy was associated with a significantly increased risk of hypotension (OR: 1.67, 95%CI: 1.48 to 1.90), whereas Dapagliflozin and Empagliflozin showed protective effects against renal adverse events. No regimen significantly increased hyperkalemia risk. Additionally, a statistically significant interaction was observed between treatment effects and baseline diabetes burden for the primary outcome (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.003).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This network meta-analysis demonstrates that while all quadruple therapy regimens improve outcomes in HFrEF, important distinctions exist. Sotagliflozin-based therapy may offer advantages in preventing hospitalizations, whereas Dapagliflozin and ARNI are comparable for mortality reduction. The safety profiles differ significantly, particularly regarding hypotension risk with ARNI and renal protection with SGLT2i. The choice of regimen should be individualized based on patient priorities, comorbidities, and safety tolerability profiles.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD420251112344<\/jats:ext-link>\n                    <\/jats:p>\n                    <jats:p>, identifier CRD420251112344.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2025.1742128","type":"journal-article","created":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T05:24:39Z","timestamp":1767331479000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparative efficacy and safety of different SGLT2 inhibitor-based combination strategies in HFrEF: a systematic review and network meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Neng","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001062","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: Executive summary: A report of the american college of Cardiology\/American heart association joint committee on clinical practice guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2016.25","article-title":"Epidemiology and aetiology of heart failure","volume":"13","author":"Ziaeian","year":"2016","journal-title":"Nat Rev Cardiol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3399\/bjgp17X691553","article-title":"Practical guidance on heart failure diagnosis and management in primary care: Recent EPCCS recommendations","volume":"67","author":"Taylor","year":"2017","journal-title":"Br J Gen Pract"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"B5","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s40265-021-01666-z","article-title":"Contemporary drug treatment of advanced heart failure with reduced ejection fraction","volume":"82","author":"Vishram-Nielsen","year":"2022","journal-title":"Drugs"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.13313","article-title":"SGLT2i versus ARNI in heart failure with reduced ejection fraction: A systematic review and meta-analysis","volume":"8","author":"Yan","year":"2021","journal-title":"ESC Heart Fail"},{"key":"B7","doi-asserted-by":"publisher","first-page":"7753","DOI":"10.1038\/s41467-022-35323-0","article-title":"Genetic architecture of heart failure with preserved versus reduced ejection fraction","volume":"13","author":"Joseph","year":"2022","journal-title":"Nat Commun"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000003118","article-title":"Pharmacotherapy in patients with heart failure with reduced ejection fraction: A systematic review and meta-analysis","volume":"138","author":"Tang","year":"2025","journal-title":"Chin Med J (Engl)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: Checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med 2015"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1234","article-title":"Incremental benefit of drug therapies for chronic heart failure with reduced ejection fraction: A network meta-analysis","volume":"20","author":"Komajda","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"B11","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"Bmj"},{"key":"B12","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"Bmj"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2355","article-title":"A randomized clinical trial on the short-term effects of 12-week sacubitril\/valsartan vs. Enalapril on peak oxygen consumption in patients with heart failure with reduced ejection fraction: Results from theACTIVITY-HF study","volume":"23","author":"Halle","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"B14","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.042929","article-title":"Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction","volume":"140","author":"Nassif","year":"2019","journal-title":"Circulation"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.3390\/jcm11102935","article-title":"Dapagliflozin impact on the exercise capacity of Non-Diabetic heart failure with reduced ejection fraction patients","volume":"11","author":"Reis","year":"2022","journal-title":"J Clin Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2020.04.008","article-title":"Effect of dapagliflozin in patients with HFrEF treated with Sacubitril\/Valsartan","volume":"8","author":"Solomon","year":"2020","journal-title":"JACC: Heart Failure"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.123.065061","article-title":"Effect of dapagliflozin versus placebo on symptoms and 6-Minute walk distance in patients with heart failure: The DETERMINE randomized clinical trials","volume":"149","author":"McMurray","year":"2024","journal-title":"Circulation"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa943","article-title":"Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes","volume":"42","author":"Abraham","year":"2021","journal-title":"Eur Heart J"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.052186","article-title":"Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF)","volume":"143","author":"Lee","year":"2021","journal-title":"Circulation"},{"key":"B21","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1001\/jamacardio.2021.4567","article-title":"Effect of treatment with Sacubitril\/Valsartan in patients with advanced heart failure and reduced ejection fraction","volume":"7","author":"Mann","year":"2022","journal-title":"JAMA Cardiol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1097\/MAJ.0b013e31829dd6b1","article-title":"Effects of spironolactone on long-term mortality and morbidity in patients with heart failure and mild or no symptoms","volume":"347","author":"Vizzardi","year":"2014","journal-title":"Am J Med Sci"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-20-0854","article-title":"Efficacy and safety of Sacubitril\/Valsartan in Japanese patients with chronic heart failure and reduced ejection fraction\u2015 results from the PARALLEL-HF study \u2015","volume":"85","author":"Tsutsui","year":"2021","journal-title":"Circ J"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2076","article-title":"OUTSTEP-HF: Randomised controlled trial comparing short-term effects of sacubitril\/valsartan versus enalapril on daily physical activity in patients with chronic heart failure with reduced ejection fraction","volume":"23","author":"Piepoli","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ahj.2021.05.005","article-title":"Sacubitril\/valsartan versus enalapril on exercise capacity in patients with heart failure with reduced ejection fraction: A randomized, double-blind, active-controlled study","volume":"239","author":"Dos Santos","year":"2021","journal-title":"Am Heart J"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2560","article-title":"Short-term effects of dapagliflozin on maximal functional capacity in heart failure with reduced ejection fraction (DAPA-VO2): A randomized clinical trial","volume":"24","author":"Palau","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"New Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/pul2.12034","article-title":"The comparative effects of sacubitril\/valsartan versus enalapril on pulmonary hypertension due to heart failure with a reduced ejection fraction","volume":"12","author":"Zhao","year":"2022","journal-title":"Pulm Circ"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1536\/ihj.19-231","article-title":"The impact of Sacrubitril\/Valsartan on clinical treatment and hs-cTnT and NT-ProBNP serum levels and the left ventricular function in patients with chronic heart failure","volume":"61","author":"Gao","year":"2020","journal-title":"Int Heart J"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01659-1","article-title":"The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: A multinational randomized trial","volume":"28","author":"Voors","year":"2022","journal-title":"Nat Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ahj.2020.07.011","article-title":"Twelve weeks of treatment with empagliflozin in patients with heart failure and reduced ejection fraction: A double-blinded, randomized, and placebo-controlled trial","volume":"228","author":"Jensen","year":"2020","journal-title":"Am Heart J"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"B33","first-page":"11","volume-title":"Eplerenone in patients with systolic heart failure and mild symptoms","author":"Zannad","year":"2011"},{"key":"B34","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2022190","volume-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","author":"Packer","year":"2020"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.028268","article-title":"Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease","volume":"137","author":"Wanner","year":"2018","journal-title":"Circulation"},{"key":"B36","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1093\/eurheartj\/ehac693","article-title":"Empagliflozin, irrespective of blood pressure, improves outcomes in heart failure with preserved ejection fraction: The EMPEROR-Preserved trial","volume":"44","author":"B\u00f6hm","year":"2023","journal-title":"Eur Heart J"},{"key":"B37","doi-asserted-by":"publisher","first-page":"12823","DOI":"10.3390\/ijms232112823","article-title":"Enhanced cardiorenal protective effects of combining SGLT2 inhibition, endothelin receptor antagonism and RAS blockade in type 2 diabetic mice","volume":"23","author":"Vergara","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.045691","article-title":"Empagliflozin in heart failure","volume":"142","author":"Griffin","year":"2020","journal-title":"Circulation"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.09380822","article-title":"Kidney-Protective effects of SGLT2 inhibitors","volume":"18","author":"Palmer","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-physiol-031620-095920","article-title":"Effects of SGLT2 inhibitors on kidney and cardiovascular function","volume":"83","author":"Vallon","year":"2021","journal-title":"Annu Rev Physiol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/s41440-024-01989-w","article-title":"Cross talk on therapeutic strategies: Natriuretic peptides and inhibiting neprilysin in hypertension management","volume":"48","author":"Jangid","year":"2025","journal-title":"Hypertens Res"},{"key":"B42","doi-asserted-by":"publisher","first-page":"200","DOI":"10.4330\/wjc.v9.i3.200","article-title":"Angiotensin receptor blocker drugs and inhibition of adrenal beta-arrestin-1-dependent aldosterone production: Implications for heart failure therapy","volume":"9","author":"Lymperopoulos","year":"2017","journal-title":"World J Cardiol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.7326\/M20-5938","article-title":"Diabetes management in chronic kidney disease: Synopsis of the 2020 KDIGO clinical practice guideline","volume":"174","author":"Navaneethan","year":"2021","journal-title":"Ann Intern Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1742128\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T05:24:40Z","timestamp":1767331480000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1742128\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,2]]},"references-count":44,"alternative-id":["10.3389\/fendo.2025.1742128"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1742128","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,2]]},"article-number":"1742128"}}